TRANSCEND: Lisocabtagene Maraleucel (liso-cel; JCAR017) Healthcare Resource Utilization in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Palomba M. Lia; Garcia Jacob; Wang Lei; Dehner Christine; Chung Karen C.; Maloney David G.

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >TRANSCEND: Lisocabtagene Maraleucel (liso-cel; JCAR017) Healthcare Resource Utilization in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

【24h】

TRANSCEND: Lisocabtagene Maraleucel (liso-cel; JCAR017) Healthcare Resource Utilization in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

机译：超越：LisocabTagene Maraleucel（Liso-cel; JCAR017）复发/难治弥漫性大B细胞淋巴瘤（DLBCL）患者的医疗资源利用

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共2页
作者
Palomba M. Lia; Garcia Jacob; Wang Lei; Dehner Christine; Chung Karen C.; Maloney David G.;
展开▼
作者单位

Mem Sloan Kettering Canc Ctr Cellular Therapeut Ctr 1275 York Ave New York NY 10021 USA;

Juno Therapeut Seattle WA USA;

Juno Therapeut Seattle WA USA;

Juno Therapeut Seattle WA USA;

Juno Therapeut Seattle WA USA;

Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. TRANSCEND: Lisocabtagene Maraleucel (liso-cel; JCAR017) Healthcare Resource Utilization in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) [J] . Palomba M. Lia, Garcia Jacob, Wang Lei, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：超越：LisocabTagene Maraleucel（Liso-cel; JCAR017）复发/难治弥漫性大B细胞淋巴瘤（DLBCL）患者的医疗资源利用
2. Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), and Other B-Cell Non-Hodgkin Lymphoma (B-NHL) Subtypes [J] . Bannerji Rajat, Arnason Jon E., Advani Ranjana, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：RegN1979的临床活性，抗CD20 x抗CD3双特异性抗体，复发/难治滤泡淋巴瘤（FL），弥漫性大B细胞淋巴瘤（DLBCL）和其他B细胞非霍奇金淋巴瘤（B. -NHL）亚型
3. A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) [J] . Kalakonda Nagesh, Cavallo Federica, Follows George, Clinical lymphoma, myeloma & leukemia . 2019,第Suppla1期

机译：复发/难治性（R / R）弥漫性大B细胞淋巴瘤（DLBCL）患者中硒克洛碱的2B研究
4. DNA Gene Expression Analysis on Diffuse Large B-Cell Lymphoma (DLBCL)Based on Filter Selection Method with Supervised Classification Method [C] . Alok Kumar Shukla, Pradeep Singh, Manu Vardhan International Conference on Computational Intelligence in Data Mining . 2019

机译：基于滤波选择法的弥漫性大B细胞淋巴瘤（DLBCL）对滤波器选择方法的DNA基因表达分析
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden [O] . Sara Harrysson, Sandra Eloranta, Sara Ekberg, 2021

机译：复发/难治性弥漫性大的B细胞淋巴瘤（DLBCL）的发生率包括瑞典群体的4243名患者的CNS复发
7. PCN262 PREFERENCE-WEIGHTED HEALTH STATUS IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL) TREATED WITH LISOCABTAGENE MARALEUCEL (LISO-CEL; JCAR017) IN THE ONGOING, MULTICENTER, PHASE 1 TRANSCEND NHL 001 TRIAL [O] . D. Patrick, L. Matza, Y. Kim, 2019

机译：用LisocabTagene Maraleucel（Liso-Cel; JCar017）处理的复发/难治性弥漫性大型B细胞淋巴瘤（R / R DLBCL）患者中的PCN262偏好加权健康状态（R / R DLBCL）在持续的，多中心，阶段1转晶NHL 001试验中

TRANSCEND: Lisocabtagene Maraleucel (liso-cel; JCAR017) Healthcare Resource Utilization in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

著录项

相似文献

相关主题

期刊订阅